A New Era in Pharmacovigilance: Toward Real‐World Data and Digital Monitoring. Issue 5 (28th February 2021)

• Record Type: Journal Article
• Authors: Lavertu, Adam; Vora, Bianca; Giacomini, Kathleen M.; Altman, Russ; Rensi, Stefano
• Is Part Of: Clinical pharmacology & therapeutics. Volume 109:Issue 5(2021)
• Page Start: 1197
• Page End: 1202
• Publication Date: 2021-02-28
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.2172
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : Adverse drug reactions (ADRs) are a major concern for patients, clinicians, and regulatory agencies. The discovery of serious ADRs leading to substantial morbidity and mortality has resulted in mandatory phase IV clinical trials, black box warnings, and withdrawal of drugs from the market. Real‐world data, data collected during routine clinical care, is being adopted by innovators, regulators, payors, and providers to inform decision making throughout the product life cycle. We outline several different approaches to modern pharmacovigilance, including spontaneous reporting databases, electronic health record monitoring and research frameworks, social media surveillance, and the use of digital devices. Some of these platforms are well‐established while others are still emerging or experimental. We highlight both the potential opportunity, as well as the existing challenges within these pharmacovigilance systems that have already begun to impact the drug development process, as well as the landscape of postmarket drug safety monitoring. Further research and investment into different and complementary pharmacovigilance systems is needed to ensure the continued safety of pharmacotherapy.